BioAtla (BCAB) Net Income towards Common Stockholders (2020 - 2026)

BioAtla's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$9.3 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 46.91% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$60.0 million, a 11.48% increase from a year earlier, with the FY2025 full-year figure at -$174.4 million, down 0.67% from the prior year.
• Net Income towards Common Stockholders retreated to -$9.3 million in Q1 2026 per BCAB's latest filing, from -$9.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$9.2 million in Q4 2025 and bottomed at -$2.8 billion in Q3 2022.
• The 5-year median for Net Income towards Common Stockholders is -$26.3 million (2025), against an average of -$219.2 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 11934.46% in 2022 and soared 98.76% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$27.9 million in 2022, then increased by 2.65% to -$27.2 million in 2023, then jumped by 42.24% to -$15.7 million in 2024, then soared by 41.5% to -$9.2 million in 2025, then declined by 1.19% to -$9.3 million in 2026.
• Per Business Quant, the three latest BCAB Net Income towards Common Stockholders figures stand at -$9.3 million (Q1 2026), -$9.2 million (Q4 2025), and -$15.3 million (Q3 2025).